TapewireFind a company

person · Reporting owner

Hansen Gwenn

Disclosed activity across 1 company

Tapewire entity
17989
SEC CIK
0001817160

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Nurix Therapeutics, Inc.NRIX · Entity 1156Chief Scientific OfficerSeptember 01, 2026September 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nurix Therapeutics, Inc.

Report date September 01, 2026 · Filed September 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect117,227 Ending reported balance After 2026-09-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-01 · Exercise / conversion · Acquired 1,452 · Balance 118,679

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Row 2 · 2026-09-01 · Sale · Disposed 1,452 · Balance 117,227

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2029-08-28Direct60,858 Reported balance After 2026-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-09-01 · Exercise / conversion · Disposed 1,452 · Balance 60,858

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 30, 2025 Filed Jul 30, 2025 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000099 · wk-form4_1753915731.xml · derivative · entry 6

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,414

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2025 Filed Jul 30, 2025 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 4,308 $12.01 $51,743.39
Disclosure

SEC source: 0001549595-25-000099 · wk-form4_1753915731.xml · nonDerivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,023

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.78 and the highest price at which shares were sold was $12.315. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2025 Filed Jul 30, 2025 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,858 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000099 · wk-form4_1753915731.xml · nonDerivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,331

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2025 Filed Jul 30, 2025 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000099 · wk-form4_1753915731.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2025 Filed Jul 30, 2025 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000099 · wk-form4_1753915731.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2025 Filed Jul 30, 2025 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000099 · wk-form4_1753915731.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,750 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · derivative · entry 7

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · derivative · entry 6

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,206 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,621

Underlying: Common Stock · 3,206 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,377 $11.50 $38,841.24
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · nonDerivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,516

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.05 and the highest price at which shares were sold was $11.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2025 Filed Apr 30, 2025 23:35 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,206 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000061 · wk-form4_1746056133.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 21:11 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 34,300 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000032 · wk-form4_1739481109.xml · derivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,300

Underlying: Common Stock · 34,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 21:11 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 75,000 $0.00 Strike: $17.12 $0.00
Disclosure

SEC source: 0001549595-25-000032 · wk-form4_1739481109.xml · derivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-02-10

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 11, 2025, until the option is fully vested on February 10, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,750 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · derivative · entry 8

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,750

Underlying: Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F8 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · derivative · entry 7

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · derivative · entry 6

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,827

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 333 $20.33 $6,768.42
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · nonDerivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,937

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.28 and the highest price at which shares were sold was $20.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,357 $19.81 $66,491.43
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · nonDerivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,270

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $19.28 and the highest price at which shares were sold was $20.275. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,877

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000022 · wk-form4_1738284487.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,877

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,750 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · derivative · entry 7

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · derivative · entry 6

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,034

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,437 $24.31 $83,536.29
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · nonDerivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,670

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000147 · wk-form4_1730334611.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,750 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · derivative · entry 7

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · derivative · entry 6

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,241

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,408 $20.67 $70,435.52
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · nonDerivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,150

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000106 · wk-form4_1722380775.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000054 · wk-form4_1714516389.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,206 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000054 · wk-form4_1714516389.xml · derivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,448

Underlying: Common Stock · 3,206 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 2,007 $12.04 $24,168.70
Disclosure

SEC source: 0001549595-24-000054 · wk-form4_1714516389.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,601

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.9050 and the highest price at which shares were sold was $12.2000. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000054 · wk-form4_1714516389.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,608

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2024 Filed Apr 30, 2024 22:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,206 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000054 · wk-form4_1714516389.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,608

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 12:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 45,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000018 · wk-form4_1707999774.xml · derivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 12:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 150,000 $0.00 Strike: $8.72 $0.00
Disclosure

SEC source: 0001549595-24-000018 · wk-form4_1707999774.xml · derivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-02-12

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000008 · wk-form4_1706658767.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000008 · wk-form4_1706658767.xml · derivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,654

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 2,334 $7.99 $18,649.13
Disclosure

SEC source: 0001549595-24-000008 · wk-form4_1706658767.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,402

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000008 · wk-form4_1706658767.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,736

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2024 Filed Jan 30, 2024 23:52 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000008 · wk-form4_1706658767.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,736

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 31, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,633 $5.20 $8,487.35
Disclosure

SEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,529

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $5.04 and the highest price at which shares were sold was $5.28. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.